Managing Multiple Medications – Polypharmacy |
0.50 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
Caring for Patients with Advanced Cancer - Part 2: Preparing for End of Life |
0.50 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
The Impact of Frontline Immune Checkpoint Inhibitors on Therapy for Relapsed/Refractory Hodgkin Lymphoma |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Debate: Is the Addition of Polatuzumab Vedotin the New Standard First-Line Therapy for Diffuse Large B-Cell Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
Updates in Melanoma: A Focus on Neoadjuvant Approaches |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
What is Optimal First-Line Management of Advanced Classic Hodgkin Lymphoma? |
0.75 |
12/01/2024 - 12:00am to 12/01/2025 - 12:00am |
CRS and ICANS Management in CAR T/Bispecific Antibody Therapies |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Management of CNS Metastases in Patients with Breast Cancer |
0.75 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
Prophylactic Vaccines/Immunizations for Cancer Patients |
0.75 |
08/04/2022 - 12:00am to 08/04/2025 - 12:00am |
Updates to Radiation Therapy for Invasive Breast Cancer with SABCS Updates |
0.75 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
Reducing Intersectional Stigmas to Improve Outcomes in People Impacted by Cancer |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Biomarker Testing and Interpretation after Breast Cancer Diagnosis |
0.75 |
03/15/2025 - 12:00am to 03/15/2026 - 12:00am |
Artificial Intelligence: Evaluation and Success Criteria for AI Tools |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Expanding the Reach of Clinical Trials |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |
Treatment for Pleural and Peritoneal Mesothelioma |
0.75 |
06/15/2025 - 12:00am to 03/01/2026 - 12:00am |